Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.59 |
| ▸ | QPCT | Q16769 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | RAD52 | P43351 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | QPCTL | Q9NXS2 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31053842 | 1.00 | PRKCI (0.59) | PRKCIQPCTKDM4EMAPTRAD52 | |
| SCHEMBL4740274 | 0.83 | PARP1 (0.52) | PRKCIQPCTKDM4EMAPTRAD52 | |
| SCHEMBL8634290 | 0.77 | QPCT (0.68) | PRKCIQPCTKDM4EMAPTRAD52 | |
| SCHEMBL8519991 | 0.74 | PRKCI (0.59) | PRKCIQPCTKDM4EMAPTRAD52 | |
| SCHEMBL110207 | 0.74 | PRKCI (0.59) | PRKCIQPCTKDM4EMAPTRAD52 | |
| SCHEMBL1286648 | 0.74 | PRKCI (0.59) | PRKCIQPCTKDM4EMAPTRAD52 | |
| SCHEMBL903277 | 0.74 | PRKCI (0.59) | PRKCIQPCTKDM4EMAPTRAD52 | |
| SCHEMBL115966 | 0.74 | PRKCI (1.00) | PRKCIQPCTKDM4EMAPTRAD52 | |
| SCHEMBL3724998 | 0.74 | PRKCI (0.59) | PRKCIQPCTKDM4EMAPTRAD52 | |
| SCHEMBL352026 | 0.74 | PRKCI (0.59) | PRKCIQPCTKDM4EMAPTRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076285-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20230060990-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | SLOAN KETTERING INST CANCER RES (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2023016518-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2021147974-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021068755-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2021-04-15 | — | — | WO | disclosed |
| EP-3733670-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Mediconns (Shanghai) Biopharmaceutical Co., Ltd (CN) | 2020-11-04 | — | — | EP | disclosed |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| US-10336757-B2 | Treatment of neurodegenerative diseases through inhibition of HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3305297-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITION OF HSP90 | Sloan-Kettering Institute for Cancer Research (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| WO-2008084218-A1 | BENZAZOLE DERIVATIVES FOR THE TREATMENT OF INFLAMMATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | disclosed |
| US-7320995-B2 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1554272-B1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | LILLY CO ELI (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | EIL LILLY AND COMPANY (US) | 2005-12-08 | — | — | US | disclosed |
| EP-1567527-A1 | CONDENSED PYRAZOLO DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1554272-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004050659-A1 | NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004014900-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | MAP3K8, MAPK8, MAPK1 | PRKCI 296/4885QPCT 3336/4885KDM4E 2781/4885 |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | PRKCI 476/4885QPCT 1574/4885KDM4E 4107/4885 |
| US-10336757-B2 | Treatment of neurodegenerative diseases through inhibition of HSP90 | HSP90AB1, HSP90B1, HSP90AA1 | PRKCI 3706/4885QPCT 2504/4885KDM4E 4392/4885 |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | PRKCI 3139/4885QPCT 830/4885KDM4E 2256/4885 |
| US-20230060990-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | HSP90B1, HSP90AB1, HSP90AB2P | PRKCI 3696/4885QPCT 2113/4885KDM4E 4480/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | PRKCI 3139/4885QPCT 830/4885KDM4E 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.